Table 4.
Herpes simplex virus infections and prostate cancer
| Study | Country | Method | Prostate cancer | Prostate non cancer controls | P value |
|---|---|---|---|---|---|
| Baker 1981 HSV 2 [70] | US |
Immunofluorescent Tissues |
34/50 68% | 81/159 51% | 0.001 s |
| Luleci 1981 HSV 2 [92] | Turkey | Serology | 14/16 88% | 22/35 63% | 0.064 ns |
| Boldogh 1983 [93] | US | ISH | 2/10 20% | 1/22 5% | 0.012 s |
| Haid 1984 HSV 2 [94] | US | Immunofluorescent tissues | 7/27 26% | 8/33 24% | 0.668 ns |
|
Leskinen 2003 HSV 1,2 [95] |
Finland | PCR tissues | 0/10 | 0/10 | |
|
Korodi 2005 HSV 2 [96] |
Finland | Serology | 11/163 7% | 20/288 7% | 0.721 ns |
| Bergh 2007 HSV 1,2 [97] | Sweden | PCR tissues | 0/201 | 0/201 | |
| Huang 2008 HSV 2 [87] |
US whites US blacks |
Serology Serology |
70/765 9% 55/103 53% |
89/915 10% 180/367 49% |
0.729 ns 0.342 ns |
| Dennis 2009 HSV 2 [98] | US |
Serology latent period tests 1 year 8 year |
26/55 47% 20/56 36% |
47/139 34% 35/156 22% |
0.002 s 0.050 s |
| Hrbacek 2011 HSV 2 [88] | Czech | Serology | 313/329 95% | 99/105 94% | 0.955 ns |
s, significant; ns, non significant